FDA needs overhaul, but what to do? It's no secret that the knives are out in Washington for the FDA. There's just been too much bad publicity for the agency over the last few years. From drug safety snafus dating as far back as Vioxx to last year's heparin scandal, from … [Read more...] about What To Do About Dysfunctional FDA
Vioxx
HPV-Vaccine, How We Got Here
Top HPV-Vaccine Researchers Join Those Advising Caution in HPV-Vaccines Gardasil and Cervarix Immunization Dr. Diane Harper was a lead researcher in the development of the HPV vaccine. Her HPV-vaccine trial papers were amongst the first I found when I started researching … [Read more...] about HPV-Vaccine, How We Got Here
Sen. Grassley (R-IA) Keeps Pharmaceutical Industry, FDA In The Crosshairs
A BIG thank you to the Philadelphia Inquirer... One of the few major media outlets that consistently cover Big Pharma and the FDA… This weekend The Philadelphia Inquirer examined how Sen. Chuck Grassley (R-Iowa) has "found a congressional calling" in "creating uproars that … [Read more...] about Sen. Grassley (R-IA) Keeps Pharmaceutical Industry, FDA In The Crosshairs
Supreme Court To Consider Federal Pre-Emption In Wyeth V. Levine
The U.S. Supreme Court next week will begin hearing the case of Wyeth v. Levine, which centers on the question of whether FDA approval of a drug warning label pre-empts product safety suits brought in state courts, the Wall Street Journal reports (Mundy/Wang, Wall Street Journal, … [Read more...] about Supreme Court To Consider Federal Pre-Emption In Wyeth V. Levine
Merck’s Post-Vioxx comeback
Stock Spotlight: Merck has had a Lazarus-like turn-around thanks to cost-cutting, new products and a savvy legal strategy. Is it still a buy? NEW YORK (CNNMoney.com) -- Merck has enjoyed a strong comeback since the messy Vioxx blowout nearly three years ago. But you might be … [Read more...] about Merck’s Post-Vioxx comeback